Literature DB >> 26897737

Can Clinical Guidelines Afford to Ignore Cost Effectiveness? An Ethical Perspective.

Kenneth Boyd1, Peter Hall2.   

Abstract

Mesh:

Year:  2016        PMID: 26897737     DOI: 10.1007/s40273-016-0391-2

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  6 in total

1.  Cancer Drugs Fund failed to collect patient outcomes.

Authors:  Holly Baker
Journal:  Lancet Oncol       Date:  2015-09-25       Impact factor: 41.316

2.  Accountability for reasonableness: an update.

Authors:  Norman Daniels; James E Sabin
Journal:  BMJ       Date:  2008-10-09

3.  UK Cancer Drugs Fund to reassess 42 agents.

Authors:  Hannah Cagney
Journal:  Lancet Oncol       Date:  2014-11-21       Impact factor: 41.316

4.  The QALY argument: a physician's and a philosopher's view.

Authors:  J Rawles; K Rawles
Journal:  J Med Ethics       Date:  1990-06       Impact factor: 2.903

5.  QALYfying the value of life.

Authors:  J Harris
Journal:  J Med Ethics       Date:  1987-09       Impact factor: 2.903

6.  Justice and the NICE approach.

Authors:  Richard Cookson
Journal:  J Med Ethics       Date:  2015-01       Impact factor: 2.903

  6 in total
  1 in total

1.  Should Low- and Middle-Income Countries Adopt Clinical Guidelines Developed in 'Rich' Countries?

Authors:  Alan Haycox
Journal:  Pharmacoeconomics       Date:  2018-07       Impact factor: 4.981

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.